JP2018537513A - １５−ｈｅｐｅを含む組成物及びその使用方法 - Google Patents

１５−ｈｅｐｅを含む組成物及びその使用方法 Download PDF

Info

Publication number
JP2018537513A
JP2018537513A JP2018531629A JP2018531629A JP2018537513A JP 2018537513 A JP2018537513 A JP 2018537513A JP 2018531629 A JP2018531629 A JP 2018531629A JP 2018531629 A JP2018531629 A JP 2018531629A JP 2018537513 A JP2018537513 A JP 2018537513A
Authority
JP
Japan
Prior art keywords
hepe
composition
subject
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018531629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537513A5 (enExample
Inventor
コウグフラン デビッド
コウグフラン デビッド
クリマク ジョン
クリマク ジョン
Original Assignee
アフィミューン リミテッド
アフィミューン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィミューン リミテッド, アフィミューン リミテッド filed Critical アフィミューン リミテッド
Publication of JP2018537513A publication Critical patent/JP2018537513A/ja
Publication of JP2018537513A5 publication Critical patent/JP2018537513A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018531629A 2015-12-18 2016-12-19 １５−ｈｅｐｅを含む組成物及びその使用方法 Pending JP2018537513A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
US62/269,280 2015-12-18
PCT/IB2016/001878 WO2017103671A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019214063A Division JP2020063259A (ja) 2015-12-18 2019-11-27 １５−ｈｅｐｅを含む組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2018537513A true JP2018537513A (ja) 2018-12-20
JP2018537513A5 JP2018537513A5 (enExample) 2019-09-19

Family

ID=57995240

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018531629A Pending JP2018537513A (ja) 2015-12-18 2016-12-19 １５−ｈｅｐｅを含む組成物及びその使用方法
JP2019214063A Pending JP2020063259A (ja) 2015-12-18 2019-11-27 １５−ｈｅｐｅを含む組成物及びその使用方法
JP2021118532A Pending JP2021178840A (ja) 2015-12-18 2021-07-19 １５−ｈｅｐｅを含む組成物及びその使用方法
JP2023118782A Pending JP2023153863A (ja) 2015-12-18 2023-07-21 １５－ｈｅｐｅを含む組成物及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019214063A Pending JP2020063259A (ja) 2015-12-18 2019-11-27 １５−ｈｅｐｅを含む組成物及びその使用方法
JP2021118532A Pending JP2021178840A (ja) 2015-12-18 2021-07-19 １５−ｈｅｐｅを含む組成物及びその使用方法
JP2023118782A Pending JP2023153863A (ja) 2015-12-18 2023-07-21 １５－ｈｅｐｅを含む組成物及びその使用方法

Country Status (18)

Country Link
US (5) US9855238B2 (enExample)
EP (2) EP4218736A3 (enExample)
JP (4) JP2018537513A (enExample)
KR (6) KR20180094516A (enExample)
CN (2) CN113230244A (enExample)
AR (2) AR107143A1 (enExample)
AU (4) AU2016370626B2 (enExample)
BR (1) BR122023026625A2 (enExample)
CA (2) CA3008774C (enExample)
ES (1) ES2948444T3 (enExample)
IL (3) IL294736A (enExample)
MX (2) MX394051B (enExample)
NZ (1) NZ744323A (enExample)
PH (1) PH12018501279A1 (enExample)
RU (2) RU2737089C2 (enExample)
SG (1) SG11201805149XA (enExample)
WO (1) WO2017103671A1 (enExample)
ZA (2) ZA201804779B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
CN108025181A (zh) 2015-07-21 2018-05-11 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014019919A1 (en) * 2012-07-30 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-ohepa and methods of using the same
JP2015522535A (ja) * 2012-05-10 2015-08-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
DE69407949T2 (de) 1993-10-01 1998-05-14 Scherer Corp R P Zusammensetzungen zum verteilen von duftstoffen
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1296923B3 (en) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
SK14502003A3 (en) 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
AU2003284617A1 (en) 2002-11-22 2004-06-18 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
CA2662987A1 (en) 2006-08-08 2008-02-21 Tethys Bioscience, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2433630A4 (en) * 2009-05-22 2014-01-08 Mochida Pharm Co Ltd SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CN104010637A (zh) 2011-10-19 2014-08-27 尊贵科学有限公司 含有双同-γ-次亚麻油酸及/或15-羟基二十碳三烯酸的药物组合物及其使用方法
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
HRP20181418T1 (hr) 2012-01-06 2018-11-30 Omthera Pharmaceuticals Inc. Dpa-obogaćeni pripravci omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
AU2013240427B2 (en) * 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MY187003A (en) * 2013-07-18 2021-08-26 Mochida Pharm Co Ltd Self-emulsifying composition of ?3 fatty acid
JP2016538288A (ja) * 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
SG10202000496XA (en) * 2014-01-10 2020-03-30 Afimmune Ltd Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016113635A1 (en) * 2015-01-16 2016-07-21 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same
HK1250345A1 (zh) * 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
CN108025181A (zh) * 2015-07-21 2018-05-11 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522535A (ja) * 2012-05-10 2015-08-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
WO2014019919A1 (en) * 2012-07-30 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-ohepa and methods of using the same

Also Published As

Publication number Publication date
BR112018012313A2 (pt) 2018-12-04
CN108697680A (zh) 2018-10-23
MX379262B (es) 2025-03-10
EP4218736A3 (en) 2023-10-18
PH12018501279A1 (en) 2019-01-28
US20230106655A1 (en) 2023-04-06
CA3008774C (en) 2021-10-12
IL318963A (en) 2025-04-01
RU2018126361A (ru) 2020-01-22
KR20240052856A (ko) 2024-04-23
JP2020063259A (ja) 2020-04-23
ZA201804779B (en) 2019-09-25
SG11201805149XA (en) 2018-07-30
US20170172965A1 (en) 2017-06-22
IL259846A (en) 2018-07-31
CA3129008A1 (en) 2017-06-22
KR20220038818A (ko) 2022-03-29
IL294736A (en) 2022-09-01
KR20250130433A (ko) 2025-09-01
CN113230244A (zh) 2021-08-10
RU2018126361A3 (enExample) 2020-01-22
ES2948444T3 (es) 2023-09-12
MX2018007390A (es) 2018-11-09
RU2020137883A (ru) 2020-12-03
US20190224154A1 (en) 2019-07-25
BR122023026625A2 (pt) 2024-01-16
MX2021000773A (es) 2022-07-19
EP4218736A2 (en) 2023-08-02
WO2017103671A1 (en) 2017-06-22
AU2022291628B2 (en) 2025-04-03
EP3389647A1 (en) 2018-10-24
US12274685B2 (en) 2025-04-15
AU2020267224A1 (en) 2020-12-10
CA3008774A1 (en) 2017-06-22
JP2023153863A (ja) 2023-10-18
AR134220A2 (es) 2025-12-10
JP2021178840A (ja) 2021-11-18
ZA202104969B (en) 2023-01-25
AU2025201593A1 (en) 2025-03-20
AU2022291628A1 (en) 2023-02-02
NZ766360A (en) 2025-05-30
KR20180094516A (ko) 2018-08-23
US20250281442A1 (en) 2025-09-11
MX394051B (es) 2025-03-24
NZ744323A (en) 2020-08-28
EP3389647B1 (en) 2023-04-05
AU2020267224B2 (en) 2022-09-29
RU2737089C2 (ru) 2020-11-24
US20180104207A1 (en) 2018-04-19
US9855238B2 (en) 2018-01-02
AU2016370626B2 (en) 2020-08-20
KR20230047501A (ko) 2023-04-07
KR20200055154A (ko) 2020-05-20
US10231945B2 (en) 2019-03-19
AU2016370626A1 (en) 2018-08-02
NZ783466A (en) 2025-05-30
AR107143A1 (es) 2018-03-28

Similar Documents

Publication Publication Date Title
US20250281442A1 (en) Compositions comprising 15-hepe and methods of using the same
KR102434817B1 (ko) 15-hepe를 포함하는 조성물 및 그의 사용 방법
JP6092843B2 (ja) 神経障害の治療用組成物
US20190216761A1 (en) Compositions comprising 15-hepe and methods of using the same
BR112018012313B1 (pt) Uso de ácido 15-hidroxieicosapentaenoico ou de um derivado farmaceuticamente aceitável do mesmo para inibir ou aliviar uma doença selecionada dentre artrite, doença de huntington, sensibilidade à insulina comprometida, psoríase, câncer de pele, diferenciação de adipócitos, dor e obesidade

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190802

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190802

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200331